All In Biotech

Drug Trial Radar · NCT04187443

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jun 2, 2020

Primary completion

Oct 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Fountain Medical Development Co., Ltd.
First posted
Dec 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.

Conditions

  • Diabetic Macular Edema
  • Macular Edema
  • Type 2 Diabetes With Diabetic Macular Edema
  • Type 1 Diabetes With Diabetic Macular Edema
  • Diabetic Retinopathy

Interventions

  • MS-553Drug

    MS-553

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventsTime frame: Baseline to Day 56

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.